Belgium's Nyxoah Q3 revenue rises on US commercialization
Belgium's Nyxoah Q3 revenue rises on US commercialization
Overview
Belgium medical device maker's Q3 revenue rose sharply yr/yr, driven by U.S. commercialization
Q3 gross margin improved to 63.1% from 60.5% a yr ago
Operating loss narrowed yr/yr as gross profit rose and R&D expenses fell
Outlook
Nyxoah expects 2026 global net revenue of €33 mln to €35 mln
Company sees 2026 gross margin between 60% and 62%
Result Drivers
U.S. COMMERCIALIZATION - Co said revenue growth was primarily driven by continued expansion of U.S. commercialization activities following FDA approval in August 2025
SURGEON TRAINING AND ACCOUNT ACTIVATION - Co cited growing base of trained surgeons and active Genio accounts in the U.S. as supporting momentum
OPERATING LEVERAGE - Co attributed improved gross margin to operating leverage on manufacturing-related costs as volumes increase
Company press release: ID:nGNXXKMsx
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Loss Per Share |
| EUR 0.18 |
|
Q3 Gross Margin |
| 63.10% |
|
Q3 Gross Profit |
| EUR 5.79 mln |
|
Q3 Loss Per Basic Share |
| EUR 0.18 |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Nyxoah SA is €4.30, about 461.4% above its November 5 closing price of €0.77
Reuters Recommended Reads
Nov 3 - Philips reaches DOJ agreement over device recall, books €288 million provision in Q3
Nov 3 - AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices
Nov 4 - LivaNova Q3 revenue beats estimates on cardiopulmonary segment strength
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Nyxoah SA
See all newsBelgium's Nyxoah Q3 revenue rises on US commercialization
Brief: Nyxoah SA Q3 Gross Profit EUR 5.785 Million
Brief: Nyxoah SA Submits Pma Supplement To FDA To Expand Genio Indication To Complete Concentric Collapse Patients
Brief: Nyxoah Says Co Appoints Liam Kelly As Chief Executive Officer Effective October 1
Brief: Cvrx Appoints John Landry As Chief Financial Officer